Literature DB >> 8305409

A new in vitro method for the simultaneous evaluation of cholesteryl ester exchange and mass transfer between HDL and apoB-containing lipoprotein subspecies. Identification of preferential cholesteryl ester acceptors in human plasma.

M Guérin1, P J Dolphin, M J Chapman.   

Abstract

To date, several methods have been developed to determine the activity of plasma lipid transfer proteins. These methods have largely involved the addition of the transfer protein in question to labeled substrates, followed by prolonged incubation (4 to 18 hours) and subsequent evaluation of the radioactivity transferred to precipitated low-density lipoprotein (LDL). While adequate for determining the activity of cholesteryl ester transfer protein (CETP), these methods generally do not take into account the composition or levels of lipoproteins present within a given individual plasma because pools of high-density lipoprotein (HDL) are labeled and used for the transfer experiments. Both the direction and the extent of lipid transfer are dependent on the composition and relative abundance of both donor and acceptor particles as well as the activity of the lipid transfer protein(s). Here we describe a new method for the determination of the capacity of plasma samples to facilitate cholesteryl ester transfer from HDL to LDL and very-low-density lipoprotein (VLDL), a method that has several advantages. First, the subject's HDL is labeled and used for transfer. Second, the labeled HDL, in a quantity equivalent to 1% of the plasma HDL mass, is added to the subject's plasma, and therefore the relative abundance of both donor and acceptor particles is preserved at their physiological levels. Third, both cholesteryl ester mass and radioactivity are determined, allowing the net mass transfer of cholesteryl ester and cholesteryl ester exchange to be quantified separately.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8305409     DOI: 10.1161/01.atv.14.2.199

Source DB:  PubMed          Journal:  Arterioscler Thromb        ISSN: 1049-8834


  15 in total

1.  In silico modeling of the dynamics of low density lipoprotein composition via a single plasma sample.

Authors:  Martin Jansen; Peter Pfaffelhuber; Michael M Hoffmann; Gerhard Puetz; Karl Winkler
Journal:  J Lipid Res       Date:  2016-03-25       Impact factor: 5.922

2.  Hepatic expression of inflammatory genes and microRNAs in pigs with high "cholesteryl ester transfer protein" (CETP) activity.

Authors:  Susanna Cirera; Benedicte C Juul Tørsleff; Christian Ritz; Merete Fredholm; Peter M H Heegaard; Kerstin Skovgaard
Journal:  Mamm Genome       Date:  2016-05-30       Impact factor: 2.957

3.  Defective functionality of HDL particles in familial apoA-I deficiency: relevance of alterations in HDL lipidome and proteome.

Authors:  Fabiana Rached; Raul D Santos; Laurent Camont; Marcio H Miname; Marie Lhomme; Carolane Dauteuille; Sora Lecocq; Carlos V Serrano; M John Chapman; Anatol Kontush
Journal:  J Lipid Res       Date:  2014-10-23       Impact factor: 5.922

4.  Plasma cholesteryl ester transfer protein and lipoprotein levels during treatment of growth hormone-deficient adult humans.

Authors:  A J Carrilho; M B Cunha-Neto; V S Nunes; A M Lottenberg; W L Medina; E R Nakandakare; N R Musolino; M D Bronstein; E C Quintão
Journal:  Lipids       Date:  2001-06       Impact factor: 1.880

5.  Impact of LDL apheresis on atheroprotective reverse cholesterol transport pathway in familial hypercholesterolemia.

Authors:  Alexina Orsoni; Elise F Villard; Eric Bruckert; Paul Robillard; Alain Carrie; Dominique Bonnefont-Rousselot; M John Chapman; Geesje M Dallinga-Thie; Wilfried Le Goff; Maryse Guerin
Journal:  J Lipid Res       Date:  2012-02-15       Impact factor: 5.922

6.  Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.

Authors:  Ronald M Krauss; Cathy Anne Pinto; Yang Liu; Amy O Johnson-Levonas; Hayes M Dansky
Journal:  J Clin Lipidol       Date:  2014-10-13       Impact factor: 4.766

7.  Plasma cholesterol efflux capacity from human THP-1 macrophages is reduced in HIV-infected patients: impact of HAART.

Authors:  Petra El Khoury; Mathilde Ghislain; Elise F Villard; Wilfried Le Goff; Caroline Lascoux-Combe; Patrick Yeni; Laurence Meyer; Corinne Vigouroux; Cécile Goujard; Maryse Guerin
Journal:  J Lipid Res       Date:  2015-01-08       Impact factor: 5.922

8.  Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr.

Authors:  Neil J Hime; Audrey S Black; David J Bonnet; Linda K Curtiss
Journal:  J Lipid Res       Date:  2014-05-12       Impact factor: 5.922

9.  Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.

Authors:  Laura K Potter; Dennis L Sprecher; Max C Walker; Frank L Tobin
Journal:  J Lipid Res       Date:  2009-03-11       Impact factor: 5.922

10.  The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.

Authors:  J W A van der Hoorn; J W Jukema; L M Havekes; E Lundholm; G Camejo; P C N Rensen; H M G Princen
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.